RapidAI Detects 33% More MeVOs Than Viz.ai, with New Real-World Data Highlighting Superior Accuracy and Clinical Insights
RapidAI, the global leader in neurovascular AI-based clinical decision support and enterprise radiology solutions, today announced compelling new study results that reaffirm its leadership in stroke imaging. The findings, presented at the European Stroke Organisation Conference (ESOC) 2025, demonstrate that RapidAI’s advanced algorithms detect 33% more medium vessel occlusions (MeVOs) than competing software Viz.ai.
The study analyzed 1,591 consecutive stroke cases at a comprehensive stroke center. Of the 1,122 eligible cases, RapidAI identified 93% (109) of MeVOs using CT Perfusion alone, compared to 70% (82) detected by Viz.ai.
“CT Perfusion is a powerful tool, but its full value is only realized when paired with high-performing software—especially in complex cases involving smaller occlusions like MeVOs,” said Harmeet Sachdev, MD, lead investigator and neurologist. “RapidAI consistently identified more occlusions than Viz in this study, echoing what we observed in the DUEL study involving large vessel occlusions. The data speaks for itself: not all AI imaging tools are equally equipped to interpret complex stroke cases.”
Understanding MeVOs
Medium vessel occlusions occur in smaller yet critical arteries such as the M2/M3 segments of the middle cerebral artery and the A1/A2 and P1/P2 segments of the anterior and posterior cerebral arteries. These blockages are harder to detect and treat but can cause devastating neurological damage if missed. The significant number of MeVOs overlooked by Viz.ai may result in delayed diagnoses and compromised outcomes.
Why RapidAI Stands Apart
RapidAI’s accuracy in CT and MR perfusion imaging has been validated in landmark stroke trials including DEFUSE 2, SWIFT PRIME, EXTEND-IA, and DEFUSE 3. Notably, RapidAI is:
- The only software proven to predict final infarct volume based on initial perfusion imaging.
- The only perfusion solution with FDA clearance to guide patient selection for mechanical thrombectomy.
“These real-world findings validate what sets RapidAI apart—deeper clinical algorithms that detect more and give providers greater clarity and confidence,” said David Stoffel, MD, Chief Business Officer at RapidAI. “Accurate perfusion imaging is essential to identifying subtle but severe strokes. Without it, critical cases go unnoticed—delaying treatment when every minute counts.”
The study, titled “AI Detection of Medium Vessel Occlusions: Evaluating Performance of RapidAI vs Viz.ai CT Perfusion in 1,591 Consecutive Code Strokes,” was presented at ESOC 2025.
About RapidAI
RapidAI is the global leader in AI-powered medical imaging analysis and coordinated stroke care. With the industry’s most clinically validated AI platform, RapidAI empowers care teams to diagnose and treat life-threatening conditions with greater speed, precision, and confidence. Trusted by thousands of hospitals in over 100 countries, RapidAI helps accelerate time to treatment, improve patient outcomes, and streamline clinical workflows. Going beyond algorithms, RapidAI drives collaboration across care teams—setting new standards in stroke and neurovascular care.
The Editorial Team at Healthcare Business Today is made up of experienced healthcare writers and editors, led by managing editor Daniel Casciato, who has over 25 years of experience in healthcare journalism. Since 1998, our team has delivered trusted, high-quality health and wellness content across numerous platforms.
Disclaimer: The content on this site is for general informational purposes only and is not intended as medical, legal, or financial advice. No content published here should be construed as a substitute for professional advice, diagnosis, or treatment. Always consult with a qualified healthcare or legal professional regarding your specific needs.
See our full disclaimer for more details.
